Restasis MultiDose is a Ophthalmic Emulsion in the Human Prescription Drug category. It is labeled and distributed by Allergan, Inc.. The primary component is Cyclosporine.
Product ID | 0023-5301_e579186c-6dfc-41c3-9cc9-a32d36352507 |
NDC | 0023-5301 |
Product Type | Human Prescription Drug |
Proprietary Name | Restasis MultiDose |
Generic Name | Cyclosporine |
Dosage Form | Emulsion |
Route of Administration | OPHTHALMIC |
Marketing Start Date | 2016-11-10 |
Marketing Category | NDA / NDA |
Application Number | NDA050790 |
Labeler Name | Allergan, Inc. |
Substance Name | CYCLOSPORINE |
Active Ingredient Strength | 1 mg/mL |
Pharm Classes | Calcineurin Inhibitor Immunosuppressant [EPC],Calcineurin Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2020-12-31 |
Marketing Start Date | 2016-11-10 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA050790 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2016-11-10 |
Marketing Category | NDA |
Application Number | NDA050790 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2016-11-10 |
Ingredient | Strength |
---|---|
CYCLOSPORINE | .5 mg/mL |
SPL SET ID: | 7224d810-bb96-4682-a942-3355e6e8061a |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0023-5301 | Restasis MultiDose | cyclosporine |
0074-3108 | Gengraf | Cyclosporine |
0074-3109 | Gengraf | Cyclosporine |
0074-7269 | Gengraf | Cyclosporine |
0078-0246 | Neoral | cyclosporine |
0078-0248 | Neoral | cyclosporine |
0023-9163 | RESTASIS | cyclosporine |
0078-0109 | Sandimmune | cyclosporine |
0078-0110 | Sandimmune | cyclosporine |
0078-0240 | Sandimmune | cyclosporine |
0078-0241 | Sandimmune | cyclosporine |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
RESTASIS MULTIDOSE 87216956 5243078 Live/Registered |
Allergan, Inc. 2016-10-26 |